Altered levels of circulating natural antibodies against VEGFR1-derived peptide in atherosclerosis

J Int Med Res. 2020 Aug;48(8):300060520948750. doi: 10.1177/0300060520948750.

Abstract

Background: Several lines of evidence have pointed to a protective role of natural antibodies in chronic diseases like atherosclerosis and cancer. Vascular endothelial growth factor receptor 1 (VEGFR1) and VEGFR2 are important regulators of angiogenesis and may be involved in the development of atherosclerosis. In this retrospective study, we developed an in-house enzyme-linked immunosorbent assay to assess whether natural IgG levels against VEGFR1 and the regulatory T cell markers CD25 and FOXP3 were associated with atherosclerosis.

Methods: A total of 218 patients with atherosclerosis and 200 healthy controls were enrolled. All patients had atherosclerotic carotid plaques. Carotid intima-media thickness was analyzed using a diagnostic ultrasound system.

Results: Plasma anti-VEGFR1 IgG levels were significantly lower in patients with atherosclerosis than control subjects. Decreased anti-VEGFR1 IgG levels were more obvious in male patients. Spearman correlation analysis showed no significant correlation between natural IgG levels and carotid intima-media thickness.

Conclusions: Decreased levels of anti-VEGFR1 IgG may be involved in development of atherosclerosis and related conditions.

Keywords: Atherosclerosis; angiogenesis; enzyme-linked immunosorbent assay; natural antibody; peptide; vascular endothelial growth factor receptor 1.

MeSH terms

  • Atherosclerosis*
  • Carotid Intima-Media Thickness
  • Humans
  • Male
  • Peptides
  • Retrospective Studies
  • Vascular Endothelial Growth Factor A
  • Vascular Endothelial Growth Factor Receptor-1*

Substances

  • Peptides
  • Vascular Endothelial Growth Factor A
  • Vascular Endothelial Growth Factor Receptor-1